Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.

Ceptur Therapeutics, a US-based targeted oligonucleotide therapeutics developer based on research at Rutgers University, launched yesterday with $75m in series A capital co-led by Qiming Venture Partners and VenBio Partners, with commitments from pharmaceutical firm Bristol Myers Squibb, Perceptive Advisors’ Xontogeny Venture Fund, Janus Henderson, Affinity Asset Advisors, Boxer Capital and LifeSci Venture Partners. Ceptur…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).